Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label dose confirmation and dosimetry study of interstitial 131I-chTNT-1/B mAb (Cotara) for the treatment of recurrent glioblastoma multiforme.

X
Trial Profile

Open-label dose confirmation and dosimetry study of interstitial 131I-chTNT-1/B mAb (Cotara) for the treatment of recurrent glioblastoma multiforme.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2011 Results will be presented by mid-2011.
    • 31 Dec 2010 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2010 Results will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top